A 0.5% w/v chloramphenicol ophthalmic solution intended for bacterial conjunctivitis and keratitis in dogs, cats, and horses is manufactured from micronized chloramphenicol base under aseptic conditions in a jacketed 316L stainless-steel vessel. The aqueous solubility of chloramphenicol base at 25°C is limited to approximately 2.5 mg/mL, so complete dissolution at 5 mg/mL requires a boric acid–sodium borate buffer system at pH 7.2–7.5 without added surfactant that could compromise corneal epithelial integrity. Dissolution is performed at 55–60°C under vacuum agitation for 20–30 min, followed by cooling to 18–22°C before pH adjustment with 0.1 N HCl or 0.1 N NaOH. The batch is then passed through a 0.45 µm prefilter and a 0.22 µm PVDF sterilizing filter into a sterilized holding tank. Multi-dose formulations use benzalkonium chloride at 0.01% w/v as preservative; preservative-free single-dose units are filled under EU GMP Annex 1 blow-fill-seal conditions. Manufacturing is conducted under 21 CFR 210/211 current GMP, and release testing includes sterility per USP <71>, particulate matter per USP <789>, and preservative efficacy per USP <51>. Terminal formats are 5 mL and 10 mL LDPE dropper bottles, and 0.3 mL single-dose ampoules. 21 CFR 530.41 prohibits extralabel use in food-producing animals; this stream is therefore restricted to companion animals, horses, and zoo species.

What Limits Direct-Compression Chloramphenicol Loading Above 60% w/w in Canine Tablets?

In solid oral dosage forms for dogs and cats, chloramphenicol base exhibits poor flow and low bulk density, making direct compression feasible only at API fractions up to approximately 40% w/w; above 60% w/w loading, the blend segregates in a 800 L bin blender and tablet weight uniformity deteriorates beyond ±3.0%. A 250 mg chloramphenicol tablet is therefore manufactured by wet granulation with a core mass of 400–450 mg, giving an API weight fraction of 55.6–62.5% w/w. The dry mix of chloramphenicol, lactose monohydrate, microcrystalline cellulose, and crospovidone is granulated in a high-shear granulator with a 5% w/w aqueous PVP K30 binder solution at 20–25°C. The wet mass is dried in a fluid bed at inlet air 55–65°C to a loss-on-drying endpoint below 2.0% w/w. Tablets are compressed on a 27-station rotary press at 15–25 kN compression force to a hardness of 8–12 kp. Capsule strengths are filled using a dosator-type machine with controlled humidity below 45% RH because static charge increases at low humidity. Release testing includes content uniformity per USP <905>, disintegration per USP <701>, and water content by Karl Fischer titration per USP <921> with a specification of not more than 0.5% w/w. Terminal dosage formats are scored tablets of 50 mg, 100 mg, 250 mg, and 500 mg, and capsules of 50 mg, 100 mg, and 250 mg filled into HDPE bottles with desiccant canisters.

Otic solution viscosity and retention in the canine external ear canal.

Otic formulations for canine otitis externa caused by susceptible Staphylococcus pseudointermedius and Escherichia coli require a vehicle that maintains contact with the auditory canal mucosa for at least 10–15 min after instillation. Chloramphenicol at 0.5% w/v is dissolved in a co-solvent system of propylene glycol and glycerin at 40–50°C under low-shear agitation; the final vehicle viscosity is typically 80–150 cP at 25°C, measured with a Brookfield viscometer spindle LV-2 at 12 rpm. The pH is adjusted to 4.5–5.5 with citrate buffer to minimize epithelial irritation while preserving chloramphenicol stability. The solution is filtered through a 0.45 µm polypropylene filter and filled into LDPE dropper bottles of 7.5 mL, 15 mL, or 30 mL. When a sterile claim is required, release testing includes sterility per USP <71> and particulate matter per USP <789>; non-sterile otic solutions are tested for microbial limits per USP <61> with total yeast and mold counts below 10 CFU/g. A companion product is a 1% w/w chloramphenicol otic ointment in a hydrocarbon base filled into 10 g aluminum tubes. Use is restricted to companion animals because 21 CFR 530.41 and Regulation (EU) No 37/2010 classify chloramphenicol as prohibited in food-producing species.

During preparation of injectable chloramphenicol formulations for hospitalized dogs, cats, and horses, the supplied base API cannot be used directly because its aqueous solubility of approximately 2.5 mg/mL at 25°C prevents a clinically practical 100 mg/mL solution. The base is therefore converted to chloramphenicol sodium succinate, which contains approximately 72.6% w/w chloramphenicol base equivalent. Each lyophilized vial is formulated to contain sodium succinate equivalent to 1.0 g chloramphenicol base, with 29–32 mg sodium hydroxide for pH adjustment and 50–100 mg mannitol or lactose as cryoprotectant. The aqueous solution is prepared at 10–15°C, aseptically filtered through a 0.22 µm PVDF membrane, filled into 10 mL Type I glass vials, and lyophilized over a 48–72 h cycle with primary drying at −35°C and secondary drying at 25°C. Terminal autoclaving is avoided because the ester hydrolyzes rapidly in solution at 121°C; after reconstitution the product is used within 24 h when stored at 2–8°C. Release testing includes bacterial endotoxins per USP <85>, sterility per USP <71>, and subvisible particulate matter per USP <790>. Finished product types are lyophilized vials of 1 g and 2 g base equivalent, reconstituted to 100 mg/mL for intravenous, intramuscular, or subcutaneous administration in companion animals and horses. 21 CFR 530.41 and Regulation (EU) No 37/2010 strictly prohibit use in food-producing species.

When a 40-mesh granule fraction is specified for nasogastric administration in horses, the wet-massing endpoint shifts.

Oral chloramphenicol powders and granules for equine and exotic animal compounding are produced by wet granulation rather than simple geometric dilution because chloramphenicol base segregates from lactose monohydrate in dry blends when particle size difference exceeds 150 µm. A typical granule formulation contains 10–25% w/w micronized chloramphenicol, 60–70% w/w lactose monohydrate, 5–10% w/w microcrystalline cellulose, and 2–5% w/w PVP K30 as binder. The wet mass is prepared in a planetary mixer at 50–60 rpm until a hand-squeeze mass forms a compact ball without free water; the endpoint is confirmed by a 40-mesh sieve retention after drying of 55–70%. Drying in a tray dryer at 50–55°C for 4–6 h reduces moisture to not more than 1.5% w/w. The dried granules are passed through a 0.8 mm oscillating granulator and blended in a 200 L V-blender for 15 min at 12 rpm. Release testing includes uniformity of dosage units per USP <905>, microbial limits per USP <61>, and water content per USP <921>; labels must state the non-food status of the animal and the prescription basis under 21 CFR 530.41 restrictions. Terminal formats are 25 g, 50 g, and 100 g HDPE jars with desiccant, or unit-dose sachets for nasogastric tube administration in horses and exotic species.

Because chloramphenicol is classified as a prohibited substance in food-producing species under 21 CFR 530.41, Regulation (EU) No 37/2010, and Codex Alimentarius Commission guidance, medicated feed premix formats containing chloramphenicol are limited to non-food-producing species such as laboratory rodents, permanently non-food equines, and zoo animals where national regulations permit compounding. A concentrated premix is prepared at 5–20% w/w chloramphenicol on a sucrose or dextrose carrier, with 0.5–1.0% w/w silicon dioxide as glidant and 0.2–0.5% w/w soybean oil as dust suppressant. Manufacturing uses a 300 L ribbon blender at 20 rpm for 10–15 min, followed by sieving through 500 µm to remove agglomerates. The premix is diluted into finished medicated feed at 0.1–1.0 kg premix per 1,000 kg feed, depending on the prescribed dose and species body mass. Premix release testing includes blend uniformity per USP <905> adapted for feed matrices and microbial limits per USP <61>; if intended for laboratory animal studies, the facility must document adherence to 21 CFR 58 Good Laboratory Practice. Terminal product types include 1 kg, 5 kg, and 25 kg multi-wall bags with polyethylene liners, labelled for non-food-species use only. Published industrial data for chloramphenicol premix inclusion in zoo species is limited; extemporaneous formulations require a veterinary prescription and site-specific stability verification.